`
[--[65.84.65.76]--]
GLENMARK
Glenmark Pharmaceuticals

1533.7 -5.70 (-0.37%)

Related News for GLENMARK

Glenmark Pharma Q2 Results: Co posts Rs 355 crore net profit on robust sales growth

 14 Nov 2024 08:41 PM

Glenmark Pharma reported Rs 340 crore net profit in Q2FY25 led by robust sales growth in India and Europe. The drugmaker reported a net loss of Rs 180 crore in the corresponding quarter of the previous year.

GLENMARK : ICHNOS GLENMARK INNOVATION (IGI) ANNOUNCES FIRST PRESENTATION OF DATA FROM PHASE 1 STUDY OF THE TRISPECIFIC ISB 2001 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/RMM) AT UPCOMING ASH ANNUAL MEETING

 06 Nov 2024 09:32 AM

GLENMARK : ICHNOS GLENMARK INNOVATION (IGI) ANNOUNCES FIRST PRESENTATION OF DATA FROM PHASE 1 STUDY OF THE TRISPECIFIC ISB 2001 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/RMM) AT UPCOMING ASH ANNUAL MEETING

GLENMARK LIFESCIENCES: DOUBLE UPGRADE BY KOTAK ON GLENMARK LIFE SCIENCES|| UPGRADE FROM REDUCE TO BUY|| 2QFY25 DENTED BY TEMPORARY CLOSURE IN ANKLESHWAR CURATED API PORTFOLIO &WITH RICH PIPELINE & CDMO CLIENT WINS TO DRIVE GROWTH

 28 Oct 2024 11:14 AM

GLENMARK LIFESCIENCES: DOUBLE UPGRADE BY KOTAK ON GLENMARK LIFE SCIENCES|| UPGRADE FROM REDUCE TO BUY|| 2QFY25 DENTED BY TEMPORARY CLOSURE IN ANKLESHWAR CURATED API PORTFOLIO &WITH RICH PIPELINE & CDMO CLIENT WINS TO DRIVE GROWTH

GLENMARK LIFE SCIENCES: Q2 EBITDA 1.3B RUPEES VS 1.7B (YOY) || Q2 EBITDA MARGIN 26.51% VS 28.06% (YOY)

 24 Oct 2024 06:56 PM

GLENMARK LIFE SCIENCES: Q2 EBITDA 1.3B RUPEES VS 1.7B (YOY) || Q2 EBITDA MARGIN 26.51% VS 28.06% (YOY)

GLENMARK LIFE SCIENCES: Q2 REVENUE 5.1B RUPEES VS 6B (YOY)

 24 Oct 2024 06:56 PM

GLENMARK LIFE SCIENCES: Q2 REVENUE 5.1B RUPEES VS 6B (YOY)

GLENMARK LIFE SCIENCES: Q2 SL NET PROFIT 953M RUPEES VS 1.2B (YOY); 1.1B (QOQ)

 24 Oct 2024 06:56 PM

GLENMARK LIFE SCIENCES: Q2 SL NET PROFIT 953M RUPEES VS 1.2B (YOY); 1.1B (QOQ)

Breakout Stocks: How to trade Divi’s Laboratories, Ipca Laboratories and Glenmark Pharma on Monday?

 13 Oct 2024 02:22 PM

Glenmark arm recalls products in US for manufacturing issues

 13 Oct 2024 12:16 PM

Glenmark Pharmaceuticals is recalling 45,504 bottles of Ryaltris Nasal Spray and 11,568 tubes of Ciclopirox Gel in the US due to manufacturing defects, including a clogged dip tube and broken tube seals. The USFDA has classified the recalls as Class II and Class III respectively.